Stryker Co. (NYSE:SYK) Shares Acquired by Blue Zone Wealth Advisors LLC

Blue Zone Wealth Advisors LLC boosted its position in shares of Stryker Co. (NYSE:SYK) by 1.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,912 shares of the medical technology company’s stock after purchasing an additional 243 shares during the period. Stryker makes up 2.2% of Blue Zone Wealth Advisors LLC’s portfolio, making the stock its 11th biggest position. Blue Zone Wealth Advisors LLC’s holdings in Stryker were worth $7,529,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the company. WD Rutherford LLC grew its holdings in Stryker by 1.6% during the 4th quarter. WD Rutherford LLC now owns 10,630 shares of the medical technology company’s stock valued at $3,827,000 after purchasing an additional 163 shares in the last quarter. Strategic Financial Concepts LLC bought a new position in Stryker during the 4th quarter valued at $55,769,000. Principal Securities Inc. boosted its stake in Stryker by 21.5% during the 4th quarter. Principal Securities Inc. now owns 7,584 shares of the medical technology company’s stock valued at $2,731,000 after acquiring an additional 1,340 shares during the last quarter. Everhart Financial Group Inc. boosted its stake in Stryker by 2.4% during the 4th quarter. Everhart Financial Group Inc. now owns 3,245 shares of the medical technology company’s stock valued at $1,168,000 after acquiring an additional 75 shares during the last quarter. Finally, Aveo Capital Partners LLC bought a new position in Stryker during the 4th quarter valued at $290,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 5.90% of the company’s stock.

Stryker Stock Down 0.9 %

SYK stock opened at $385.05 on Friday. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The company has a market capitalization of $146.79 billion, a price-to-earnings ratio of 49.62, a price-to-earnings-growth ratio of 2.98 and a beta of 0.96. The firm’s 50-day moving average is $377.31 and its two-hundred day moving average is $366.66. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the business posted $3.46 EPS. On average, analysts forecast that Stryker Co. will post 13.49 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.87%. Stryker’s payout ratio is currently 43.30%.

Analysts Set New Price Targets

A number of research firms have commented on SYK. Piper Sandler reiterated an “overweight” rating and set a $420.00 price objective (up from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. Evercore ISI increased their price objective on shares of Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Truist Financial lifted their price target on shares of Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a report on Thursday, January 30th. Robert W. Baird lifted their price target on shares of Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Finally, Royal Bank of Canada lifted their price target on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and a consensus price target of $420.68.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.